Evidence Explorer · MS-N294 · Nutrition and dietary patterns · Appraised November 10, 2026
The AMPLIFY randomized trial produced clinically meaningful six-month weight loss and better diet quality in selected cancer survivors. It did not test recurrence or survival.
Evidence at a glance
- Population: 349 survivors aged 50 years or older, BMI 25 to under 50 kg/m², after one of nine obesity-related cancers with greater than 70% five-year survival.
- Intervention: a 24-week fully automated, tailored web program targeting approximately 0.5 kg weight loss per week and improved diet quality; comparator was a waitlist.
- Primary result: between-arm percent weight change was −4.75% (95% CI −6.04 to −3.46).
- Secondary findings: waist circumference was 3.47 cm lower and diet quality improved; leptin and a cognitive score also differed.
- Evidence label: positive randomized weight-loss evidence; recurrence and survival not established.
- Evidence label: Positive weight-loss result; cancer outcomes untested.
What was studied
The program delivered serialized, personalized behavioral guidance without routine live coaching. More participants achieved 3%, 5% and 10% weight-loss thresholds than with waitlist control.
Weight, waist circumference, blood pressure and metabolic markers are relevant survivorship outcomes. They cannot establish that the program prevents cancer recurrence. The waitlist design also does not separate specific program content from attention and expectancy effects as well as an active comparator would.
What this evidence cannot establish
Follow-up was six months, eligibility selected relatively favorable-prognosis survivors, and long-term weight maintenance was not established. The trial was not designed for recurrence, survival, treatment tolerance or cancer-specific symptoms.
Safety and practical context
Intentional weight loss is not appropriate for everyone with cancer. People with active weight loss, cachexia, sarcopenia, frailty or treatment-related poor intake need nutrition restoration rather than calorie restriction. Preserving muscle through adequate protein and resistance activity is an important companion goal.
Questions for the care team
- Is intentional weight loss appropriate for my treatment phase and nutritional status?
- How will we track muscle and function rather than weight alone?
- What support is available if automated guidance is not enough or eating concerns emerge?
Sources and identifiers
- AMPLIFY randomized trial — PMID 41911893
Funding and conflicts: Supported by National Cancer Institute grants including R01 CA242737, P01 CA229997, R01 CA246695 and R25 CA076023. Full conflict disclosures were not available in the abstract-level appraisal.
Source access and dates: Primary reports, registries and official guidance available through the links above were checked November 10, 2026. Last literature search November 10, 2026. Fields unavailable from accessible full text are labeled not reported or not verified rather than assumed absent.
Educational evidence summary, not individualized medical advice. Restrictive diets or supplements should not replace established cancer treatment or adequate nutrition. Symptom, weight, biomarker, laboratory, imaging, pathology or animal findings do not by themselves establish tumor control, recurrence prevention or longer survival.
